This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Dalantercept
- DrugBank Accession Number
- DB14988
- Background
Dalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Dalantercept
- External IDs
- ACE-041
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Dalantercept. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Dalantercept. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Dalantercept. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dalantercept. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Dalantercept. Amivantamab The risk or severity of adverse effects can be increased when Dalantercept is combined with Amivantamab. Anifrolumab The risk or severity of adverse effects can be increased when Anifrolumab is combined with Dalantercept. Ansuvimab The risk or severity of adverse effects can be increased when Dalantercept is combined with Ansuvimab. Anthrax immune globulin human The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Dalantercept. Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Dalantercept. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Activin Receptors
- Amino Acids, Peptides, and Proteins
- Blood Proteins
- Enzymes
- Enzymes and Coenzymes
- Globulins
- Immunoglobulin Constant Regions
- Immunoglobulin Fragments
- Immunoglobulins
- Immunoproteins
- Intracellular Signaling Peptides and Proteins
- Membrane Proteins
- Peptide Fragments
- Peptides
- Phosphotransferases
- Phosphotransferases (Alcohol Group Acceptor)
- Protein Kinases
- Protein-Serine-Threonine Kinases
- Proteins
- Receptors, Growth Factor
- Receptors, Peptide
- Receptors, Transforming Growth Factor beta
- Recombinant Proteins
- Serum Globulins
- Transferases
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- EGC16R10V0
- CAS number
- 1186210-24-1
References
- General References
- Not Available
- External Links
- Wikipedia
- ALK_inhibitor
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Endometrial Adenocarcinomas / Endometrial Clear Cell Adenocarcinoma / Endometrial Mixed Adenocarcinoma / Endometrial Mucinous Adenocarcinoma / Endometrial Papillary Serous Carcinoma / Endometrial Squamous Cell Carcinoma / Endometrial Transitional Cell Carcinoma / Endometrial Undifferentiated Carcinoma / Recurrent Uterine Corpus Carcinoma 1 2 Completed Treatment Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma 1 2 Completed Treatment Squamous Cell Carcinoma of the Head and Neck (SCCHN) 1 2 Terminated Treatment Advanced Renal Cell Carcinoma 1 1 Completed Treatment Advanced Solid Tumors / Multiple Myeloma (MM) 1 1, 2 Completed Treatment Advanced Adult Hepatocellular Carcinoma 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at May 20, 2019 14:39 / Updated at February 21, 2021 18:55